Stockscreener 앱 받기
10.88
0.78%
-0.085
시간 외 거래:
10.81
-0.065
-0.60%
Artiva Biotherapeutics Inc 주식(ARTV)의 최신 뉴스
Artiva Biotherapeutics' SWOT analysis: NK cell therapy stock poised for growth - Investing.com
Cantor Fitzgerald Forecasts ARTV FY2024 Earnings - Defense World
Cantor Fitzgerald Weighs in on ARTV FY2024 Earnings - MarketBeat
Wedbush Has Bearish Estimate for ARTV FY2024 Earnings - Defense World
Wedbush Lowers Earnings Estimates for Artiva Biotherapeutics - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Issues Quarterly Earnings Results, Misses Estimates By $0.24 EPS - MarketBeat
Artiva Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Needham & Company LLC - MarketBeat
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference - The Manila Times
Artiva Bio to Present at Jefferies Healthcare Conference, Spotlight on Cell Therapy Pipeline | ARTV Stock News - StockTitan
Artiva Biotherapeutics (NASDAQ:ARTV) vs. Iovance Biotherapeutics (NASDAQ:IOVA) Critical Review - Defense World
Cell therapy developer Artiva refiles for a $100M IPO - MSN
Artiva Biotherapeutics appoints new board member By Investing.com - Investing.com Australia
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors - ForexTV.com
Artiva Biotherapeutics, Inc. Appoints Alison Moore as an Independent Member of Its Board of Directors - Marketscreener.com
Artiva Biotherapeutics appoints new board member - Investing.com
Artiva, Century, others extend natural-killer autoimmune push - BioWorld Online
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4%Time to Sell? - MarketBeat
Wall Street SWOT: Artiva Biotherapeutics stockNK cell pioneer targets autoimmune market By Investing.com - Investing.com South Africa
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying - 24/7 Wall St.
Artiva Biotherapeutics (NASDAQ:ARTV) Trading 6.2% Higher - MarketBeat
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Quiet Period Will End on August 28th - Defense World
Artiva Biotherapeutics, Inc.'s Quiet Period Set To Expire on August 28th (NASDAQ:ARTV) - MarketBeat
Brokers Issue Forecasts for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV) - MarketBeat
Analysts Set Expectations for Artiva Biotherapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Quotes, Forecast and News Summary - Benzinga
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch - Benzinga
Artiva Biotherapeutics (NASDAQ:ARTV) Receives New Coverage from Analysts at TD Cowen - Defense World
Needham & Company LLC Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Wedbush Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Cantor Fitzgerald - Defense World
Non-Hodgkin Lymphoma Drugs Pipeline 2024 | Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc - Barchart
July IPOs to Watch in Tech, Biotech, Food Security and Transportation - Investorideas.com newswire
Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares - 24/7 Wall St.
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal - Seeking Alpha
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Yong-Jun Huh Buys 2,083,332 Shares - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Major Shareholder Global Strategic Fund I. Venbio Purchases 416,666 Shares - Defense World
VenBio fund acquires $5m in Artiva Biotherapeutics stock By Investing.com - Investing.com Australia
VenBio fund acquires $5m in Artiva Biotherapeutics stock - Investing.com India
Artiva Biotherapeutics sees major stock purchases by GC Corp entities - Investing.com South Africa
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO By Investing.com - Investing.com South Africa
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO - Investing.com India
0.93%
3.55%
자본화:
|
볼륨(24시간):